Roxadustat
- Generic Name
- Roxadustat
- Brand Names
- Evrenzo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16N2O5
- CAS Number
- 808118-40-3
- Unique Ingredient Identifier
- X3O30D9YMX
- Background
Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. Roxadustat was first approved by...
- Indication
Roxadustat is indicated for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
- Associated Conditions
- Anemia
- Associated Therapies
- -
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 161
- Registration Number
- NCT01147666
ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01083888
Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 117
- Registration Number
- NCT00761657
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath